CA4 and cancer: Prodrug-assembled polymeric nanoparticles for the delivery of two drugs [CA4 and 7-ethyl- 10-hydroxycamptothecin (SN38)] in a sequential manner on demand at the target site was developed by Hangxiang Wang et al. CA4, an antiangiogenic agent, can disrupt the tumor neovasculature, causing vascular shutdown, while SN38, a chemotherapeutic drug, can inhibit the DNA topoisomerase 1 of cancer cells.